SCND SCIENTIFIC INDUSTRIES INC
Laboratory Analytical Instruments · OTC · SEC CIK 87802 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.6%
TTM net income YoY-244.6%
TTM EPS YoY-208.3%
Revenue 3-yr CAGR-19.6%
Net income 3-yr CAGR—
Margins
Gross margin31.3%
Operating margin-116.3%
Net margin-75.1%
FCF margin-110.6%
EBITDA margin-110.8%
Returns
ROE-40.4%
ROA-33.5%
ROIC (approx.)-56.1%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets20.7%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio15.4%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.05M | $4.80M |
| Cost of revenue | $3.75M | $2.79M |
| Gross profit | $1.30M | $2.01M |
| R&D expense | $2.49M | $2.90M |
| SG&A expense | $3.27M | $4.12M |
| Operating income | -$7.89M | -$8.22M |
| Pretax income | -$1.78M | -$8.02M |
| Income tax | $4,600 | $0 |
| Net income | -$1.22M | -$6.45M |
| EBITDA | -$7.28M | -$7.47M |
| EPS (diluted) | -0.11 | -0.61 |
| Weighted avg. shares (diluted) | 11.34M | 10.50M |
| Balance sheet | ||
| Cash & equivalents | $955,000 | $587,900 |
| Short-term investments | $5.71M | — |
| Receivables | $865,800 | $581,900 |
| Inventory | $1.75M | $2.06M |
| Current assets | $10.39M | $8.29M |
| PP&E, net | $690,900 | $796,300 |
| Goodwill | $115,300 | $115,300 |
| Intangibles | $103,500 | $752,300 |
| Total assets | $12.61M | $11.56M |
| Current liabilities | $1.35M | $1.75M |
| Total liabilities | $1.94M | $2.44M |
| Shareholders' equity | $10.66M | $9.12M |
| Shares outstanding | 11.93M | 10.50M |
| Cash flow statement | ||
| Operating cash flow | -$8.15M | -$3.05M |
| Capital expenditure | $63,200 | $98,900 |
| Free cash flow | -$8.21M | -$3.15M |
| Investing cash flow | $3.83M | $2.87M |
| Financing cash flow | $1.95M | $645,700 |
| Depreciation & amortization | $610,000 | $750,700 |
| Stock-based compensation | $520,700 | $1.17M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.